630 filings
Page 7 of 32
4
XLRN
Acceleron Pharma Inc
6 Jul 20
ACCELERON PHARMA / CORP /DE/ CELGENE ownership change
5:24pm
3
XLRN
Acceleron Pharma Inc
6 Jul 20
Initial statement of insider ownership
5:22pm
8-K
XLRN
Acceleron Pharma Inc
2 Jul 20
Other Events
12:00am
424B2
XLRN
Acceleron Pharma Inc
2 Jul 20
Prospectus for primary offering
12:00am
424B5
XLRN
Acceleron Pharma Inc
29 Jun 20
Prospectus supplement for primary offering
12:00am
8-K
XLRN
Acceleron Pharma Inc
26 Jun 20
Other Events
5:22pm
8-K
XLRN
Acceleron Pharma Inc
24 Jun 20
Regulation FD Disclosure
3:17pm
SC 13G/A
BLK
Blackrock Inc.
9 Jun 20
ACCELERON PHARMA / BlackRock ownership change
4:33pm
4
Christopher Hite
5 Jun 20
ACCELERON PHARMA / Christopher Hite ownership change
8:32pm
3
XLRN
Acceleron Pharma Inc
5 Jun 20
ACCELERON PHARMA / Christopher Hite ownership change
8:23pm
8-K
XLRN
Acceleron Pharma Inc
4 Jun 20
Departure of Directors or Certain Officers
5:17pm
10-Q
2020 Q1
XLRN
Acceleron Pharma Inc
Quarterly report
11 May 20
4:14pm
8-K
XLRN
Acceleron Pharma Inc
11 May 20
Acceleron Reports First Quarter 2020 Operating and Financial Results
4:10pm
8-K
XLRN
Acceleron Pharma Inc
5 May 20
Reblozyl® (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
5:06pm
DEFA14A
XLRN
Acceleron Pharma Inc
16 Apr 20
Additional proxy soliciting materials
4:35pm
DEF 14A
XLRN
Acceleron Pharma Inc
Definitive proxy
16 Apr 20
4:33pm
4
Veness Adam M
10 Apr 20
ACCELERON PHARMA / Adam M Veness ownership change
5:30pm
4
XLRN
Acceleron Pharma Inc
10 Apr 20
ACCELERON PHARMA / KEVIN F MCLAUGHLIN ownership change
5:29pm
8-K
XLRN
Acceleron Pharma Inc
9 Apr 20
Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension
5:26pm
8-K
XLRN
Acceleron Pharma Inc
7 Apr 20
Departure of Directors or Certain Officers
4:39pm